Alexandre Iannello
Overview
Explore the profile of Alexandre Iannello including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
2035
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vitorino P, Chuang C, Iannello A, Zhao X, Anderson W, Ferrando R, et al.
Transl Oncol
. 2020 Oct;
14(1):100883.
PMID: 33074129
Rovalpituzumab tesirine (Rova-T) offers a targeted therapy for ~85% of SCLC patients whose tumors express DLL3, but clinical dosing is limited due to off-target toxicities. We hypothesized that a sub-efficacious...
2.
Samarani S, Mack D, Bernstein C, Iannello A, Debbeche O, Jantchou P, et al.
PLoS One
. 2019 Jun;
14(6):e0217767.
PMID: 31194766
Background: Killer-cell Immunoglobulin-like Receptor (KIR) genes encode receptors, which are mainly expressed on, and control functional activities of, Natural Killer (NK) cells. There exist six distinct activating KIR genes in...
3.
Hsu J, Hodgins J, Marathe M, Nicolai C, Bourgeois-Daigneault M, Trevino T, et al.
J Clin Invest
. 2018 Sep;
128(10):4654-4668.
PMID: 30198904
Checkpoint blockade immunotherapy targeting the PD-1/PD-L1 inhibitory axis has produced remarkable results in the treatment of several types of cancer. Whereas cytotoxic T cells are known to provide important antitumor...
4.
Iannello A, Samarani S, Allam O, Jenabian M, Mehraj V, Amre D, et al.
Cytokine
. 2016 Nov;
90:96-99.
PMID: 27863336
An imbalance between IL-18 and its antagonist, IL-18 Binding Protein, occurs in the circulation of HIV-infected individuals. We show here for the first time that HIV-infected Long Term Non-Progressors (LTNPs)...
5.
Spiegel A, Brooks M, Houshyar S, Reinhardt F, Ardolino M, Fessler E, et al.
Cancer Discov
. 2016 Apr;
6(6):630-49.
PMID: 27072748
Unlabelled: Immune cells promote the initial metastatic dissemination of carcinoma cells from primary tumors. In contrast to their well-studied functions in the initial stages of metastasis, the specific roles of...
6.
Iannello A, Thompson T, Ardolino M, Marcus A, Raulet D
Curr Opin Immunol
. 2015 Dec;
38:52-8.
PMID: 26686774
Increasing evidence supports a role for innate immune effector cells in tumor surveillance. Natural killer (NK) cells and myeloid cells represent the two main subsets of innate immune cells possessing...
7.
Gowen B, Chim B, Marceau C, Greene T, Burr P, Gonzalez J, et al.
Elife
. 2015 Nov;
4.
PMID: 26565589
Recognition and elimination of tumor cells by the immune system is crucial for limiting tumor growth. Natural killer (NK) cells become activated when the receptor NKG2D is engaged by ligands...
8.
Deng W, Gowen B, Zhang L, Wang L, Lau S, Iannello A, et al.
Science
. 2015 Mar;
348(6230):136-9.
PMID: 25745066
Immune cells, including natural killer (NK) cells, recognize transformed cells and eliminate them in a process termed immunosurveillance. It is thought that tumor cells evade immunosurveillance by shedding membrane ligands...
9.
Ardolino M, Azimi C, Iannello A, Trevino T, Horan L, Zhang L, et al.
J Clin Invest
. 2014 Oct;
124(11):4781-94.
PMID: 25329698
Various cytokines have been evaluated as potential anticancer drugs; however, most cytokine trials have shown relatively low efficacy. Here, we found that treatments with IL-12 and IL-18 or with a...
10.
Iannello A, Raulet D
Oncoimmunology
. 2014 May;
3(1):e27616.
PMID: 24800169
We recently dissected how senescent tumors can trigger complementing signaling pathways that mobilize natural killer (NK) cells to eliminate malignant cells. In addition to cell-intrinsic effects on proliferation, senescence induces...